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Summary  The  increase  in  number  of  implanted  cardiac  medical  devices  and  the  announced
decrease  in  number  of  cardiologists  have  led  to  remote  monitoring  being  considered  as  a  pivotal
tool for  patient  follow-up.  For  10  years,  remote  monitoring  has  been  the  subject  of  multiple
clinical studies.  In  these  studies,  reliability  and  clinical  efﬁcacy  have  been  demonstrated,  but
the use  of  remote  monitoring  remains  quite  limited  in  France  compared  with  other  countries.  To
explain this  delay  in  uptake,  some  organizational  difﬁculties  and  the  lack  of  reimbursement  of
remote monitoring  are  often  mentioned.  The  results  of  medico-economic  studies  might  provide
answers about  the  value  of  remote  monitoring  and  enable  the  supervisory  authorities  to  deﬁne
how its  use  will  be  ﬁnanced.  This  review  provides  a  global  view  of  remote  monitoring  in  France,
and covers  the  principle,  clinical  efﬁcacy,  organizational  and  regulatory  aspects,  and  medico-
economic data.
©  2014  Elsevier  Masson  SAS.  All  rights  reserved.Abbreviations: AF, atrial ﬁbrillation; CAD, Canadian dollars; CRT, cardiac resynchronization therapy; GHS, homogeneous hospital stay
groups (groups homogènes de séjours); LPPR, List of Reimbursable Products and Services (Liste des Produits et Prestations Remboursables);
RM, remote monitoring; USD, United States dollars.
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Résumé  La  télécardiologie  est  considérée  comme  une  approche  particulièrement  promet-
teuse pour  le  suivi  des  patients  au  regard  du  nombre  croissant  de  dispositifs  médicaux  cardiaques
implantés  et  de  la  diminution  du  nombre  de  cardiologues  envisagée  dans  les  prochaines  années.
Depuis 10  ans,  la  télécardiologie  a  fait  l’objet  de  multiples  études  cliniques.  Dans  ces  études,  la
ﬁabilité et  l’efﬁcacité  clinique  ont  été  démontrées.  Malgré  ces  résultats,  le  déploiement  de  la
télécardiologie  reste  limité  en  France  en  comparaison  des  autres  pays.  Pour  expliquer  ce  retard,
des difﬁcultés  organisationnelles  et  le  manque  de  valorisation  de  l’activité  de  télécardiologie
sont souvent  mis  en  avant.  Les  résultats  des  études  médico-économiques  pourraient  permet-
tre aux  autorités  de  tutelles  de  déﬁnir  des  modalités  adaptées  de  ﬁnancement.  Cette  revue
a pour  objectif  de  faire  un  état  des  lieux  de  la  télécardiologie  (principe,  efﬁcacité  clinique,
organisation,  aspects  réglementaires,  données  médico-économiques).
© 2014  Elsevier  Masson  SAS.  Tous  droits  réservés.
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qackground
he  number  of  implantations  of  electronic  implantable
edical  devices  in  the  cardiovascular  area  has  grown  since
heir  introduction  in  1958  [1].  In  France,  65,000  pacemakers
re  implanted  every  year.  The  number  of  implantable  deﬁb-
illators  rose  from  2700  in  2003  to  13,000  in  2013.  These
edical  devices  require  regular  post-implantation  follow-
p  of  patients  to  ensure  that  an  appropriate  response  to
he  patient’s  condition  is  transmitted.  Monitoring  of  battery
tatus  is  also  essential.  Currently,  conventional  monitoring
face-to-face  four  times  per  year)  does  not  allow  real-time
ollow-up.  Technological  advances,  with  the  development  of
mplantable  devices  with  automatic  remote  monitoring  (RM)
apability,  allow  constant  surveillance.
RM  involves  the  transmission  of  data  on  the  status
f  the  device,  patient  variables  gathered  by  the  device
nd,  sometimes,  disease-related  data,  over  a  network  from
he  patient’s  location  via  a  central  database  to  a  hospi-
al  or  physician’s  ofﬁce.  RM  could  also  be  a  solution  to
he  decrease  in  the  number  of  practitioners  envisaged  in
he  coming  years  as  opposed  to  the  predicted  increase
n  the  number  of  patients.  The  increase  in  patients  can
e  explained  by  the  ageing  of  the  population  and  the
idening  of  heart  failure  indications,  thanks  to  the  devel-
pment  of  cardiac  resynchronization  therapy  (CRT)  devices
2].
Currently,  ﬁve  manufacturers  offer  monitoring  inter-
aces,  which  provide  follow-up  of  20,000  patients  in  France
3].  These  monitoring  interfaces  exhibit  differences.  The
linical  and  organizational  impact  of  RM  has  already  been
upported  by  a  large  number  of  publications.  Although  the
mplantation  of  electronic  medical  devices  is  currently  cov-
red  by  health  insurance,  the  deployment  of  RM  remains
ubject  to  the  supervisory  authorities  of  the  RM  act  itself
n  France,  unlike  in  other  countries.  Validation  of  the  act
ay  evolve  in  the  coming  years  and  should  be  the  subject
f  robust  medico-economic  studies.This  review  ﬁrstly  offers  a  reminder  of  the  principle  of
M.  Secondly,  the  organizational  and  regulatory  aspects  of
M  will  be  discussed,  followed  by  medico-economic  aspects
nherent  to  RM.
t
A
Rhe principle of cardiac remote
onitoring
he  principle  of  cardiac  RM  was  ﬁrst  mentioned  in  the
970s  by  Dreifus  and  Pennock  [4]. With  the  recent  progress
n  telecommunications,  RM  has  rapidly  become  a  powerful
ool  in  the  rhythmology  department.  Initially,  active  sys-
ems  were  developed  but  were  soon  replaced  by  automatic
ransmission,  which  increases  patient  observance  naturally.
Implantable  devices  with  automatic  RM  capability  are
quipped  with  an  antenna  circuit  and  transmit  daily  infor-
ation  as  electromagnetic  signals  to  a  transmitter  located
n  the  patient’s  home.  The  transmitter  automatically  trans-
its  this  information  after  encoding  via  the  mobile  phone
r  landline  network  to  the  secure  server  managed  by  the
anufacturer.  The  analysis  of  information  is  then  possible
rom  the  cardiology  centre  due  to  a  secure  internet  portal.
wo  different  types  of  data  are  transmitted  to  the  implant
entre.  Firstly,  data  on  the  medical  device  integrity  are
vailable:  battery  status;  recording  and  stimulation  capac-
ty;  and  measurement  of  impedance  lead.  Secondly,  cardiac
vents  in  patients  are  transmitted  (see  later).  All  abnormal-
ties  are  reported  by  e-mail,  facsimile,  telephone  and/or
hort  message  service  (SMS)  to  the  health  professional  in
harge  of  monitoring.
There  are  currently  ﬁve  manufacturers  offering  RM
ystems  (Table  1),  which  operate  differently  (Table  2),  espe-
ially  in  terms  of  location  of  data  storage  and  encoding  used.
he  notiﬁcation  of  alerts,  as  well  as  the  management  of  end
f  monitoring  and  registration  of  new  patients,  can  be  con-
gured  according  to  the  needs  of  the  rhythmology  centre.
he  Home  Monitoring® system  does  not  allow  the  patient
o  activate  the  transmission.  With  the  exception  of  Boston
cientiﬁc,  all  systems  use  the  mobile  network.  As  transmis-
ions  need  energy  from  the  device,  RM  reduces  the  lifetime
f  implants  by  1—6  months,  according  to  the  prosthesis.  The
atitude® system  avoids  this  pitfall  due  to  the  transmitter
uerying  the  prosthesis  that  supplies  the  energy.Data  storage  is  not  carried  out  in  France,  except  for
he  systems  developed  by  Sorin  and  Boston  Scientiﬁc.
ll  systems  authorize  access  by  the  treating  physician.
egarding  the  rules  of  conﬁdentiality,  many  countries  allow
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Table  1  List  of  suppliers  of  remote  monitoring  systems  on  the  French  market.
Supplier  Remote  monitoring  system  Compatibility  LPPR  (with  MD)
Biotronik  Home  Monitoring® (Cardio
Messenger)
Stimulators:  Evia®
IAD:  Lumax®
Registered  (Lumax®)
Boston  Scientiﬁc  Latitude  Patient
Management  System®
IAD:  Teligen®/Cognis®/Incepta® Registered
(Teligen®/Cognis®/Incepta®)
Medtronic  Carelink  Network® Holter:  Reveal®
Stimulators:  Advisa®/Adapta®
IAD:
Evera®/Viva®/Secura®/Consulta®/Virtuoso®/Protecta®
Registered
(Evera®/Protecta®/Viva®)
St.  Jude  Medical  Merlin  Patient  Care  System® IAD:  Ellipse®/Current®/Fortify®/
Analyst®/Assura®/Atlas®/Unify®
Registered
(Ellipse®/Current®/Fortify®/
Analyst®)
Sorin  Smartview® IAD:  Paradym  RF®/Intensia® Not  registered  on  01/01/2014
IAD: implantable automatic deﬁbrillator; LPPR: List of Reimbursable Products and Services; MD: medical device.
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•manufacturers  to  dispose  of  the  patient  data;  this  is  not  the
case  in  France,  where  patient  data  are  conﬁdential  and  can
only  be  consulted  by  the  rhythmology  department.
The  feasibility  and  reliability  of  RM  has  been  demon-
strated  for  a  number  of  manufacturers  across  several
publications  [5—9].  In  these  studies  (Biotronik,  Medtronic,
Boston  Scientiﬁc),  messages  were  received  in  their  entirety
and  were  delivered  in  <  1  minute  to  the  rhythmology  centre
in  >  90%  of  cases  [7].  The  correlation  coefﬁcient  between  the
transmitted  data  and  those  collected  by  device  querying  was
95%  [5].  Three  manufacturers  allow  a  wire-line  transmission,
which  is  useful  in  areas  not  covered  by  the  Global  System  for
Mobile  Communications  (GSM)  network,  covering  99%  of  the
metropolitan  area  (Table  2).
p
i
tInitially,  RM  systems  transmit  data  on  the  prosthesis  and
robe  integrity,  as  well  as  on  cardiac  events  in  patients.  The
eports  allow  detection  of:
failure  of  the  implants  to  charge  and  deliver  appropriate
therapy;
inappropriate  ventricular  tachycardia  and  intermittent  T-
wave  oversensing;
a change  in  lead  impedance  that  could  reﬂect  a  lead  frac-
ture.As  a  function  of  the  medical  devices  implanted  in
atients,  data  are  different,  and  the  complexity  of  the
mplants  increases  the  amount  of  data  transmitted.  With
he  development  of  CRT  devices,  new  variables  have  been
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Table  2  Comparison  of  intrinsic  performance  of  remote  monitoring  systems.
Supplier
Biotronik  Boston  Scientiﬁc Medtronic  St.  Jude  Medical  Sorin
Transmission  of  data
Manual  x  x  (for  Holter  &
stimulator)
x  x
Automatic  x  x  x  (for  DCI)  x  x
Scheduled  x  x  x  (for  DCI)  x  x
Network  used
Landline  x  x  x
Mobile  x  x  (Orange  +++)  x  x  (Orange  +++)
Internet  x
Data  storage  Germany  France  Netherlands  USA  France
ASIP  agreement  x  (pending)  No,  but  agreement
at  European  level
x  (pending)  x  x
Data  encryption  x  x  x  x  x
Access  to  data  Germany  France  Netherlands  USA  France
Implant  centre x  x  x  x  x
Cardiologist  x  x  x  x  x
Supplier  x
Means  of  notifying  alerts
Telephone x
Fax  x  x  x
Mail  x  x  x  x  x
SMS  x  x  x  x
Color  code  of  alerts
Red  and  yellow x  x  x  x
Orange  and  white x
ASIP: Agence des systèmes d’information partagés; DCI: data converter interface; SMS: short message service.
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Aroposed  to  follow-up  patients  with  heart  failure  [10].
eight  and  blood  pressure  are  particularly  useful  for
onitoring  aggravation  of  heart  failure.  Pulmonary  artery
ressure  is  also  followed  up  with  these  new  devices  and
ives  important  information  for  rapid  patient  management.
ll  the  data  downloaded  from  these  increasingly  complex
evices  need  careful  management  and  highlight  the  impor-
ance  of  a  well-organized  RM  procedure.
dentiﬁcation of device defects
efects  in  pacemakers  and  deﬁbrillators  are  rare  but  can  be
ramatic  in  patients  without  efﬁcient  escape  rhythm  [11].
he  deﬁbrillation  leads  are  complex  structures  of  multi-
le  conductors  associated  with  high-energy  release  systems.
ajor  dysfunctions  cause  inappropriate  shocks  or  potential
oss  of  function.  The  clinical  consequences  are  uncomfort-
ble  shocks  for  the  patient  or  a  pro-arrhythmic  effect  that
an  be  life  threatening  [12].  In  recent  years,  a  growing  num-
er  of  medical  device  vigilance  signals  and  alerts  relating
o  active  implantable  cardiac  medical  devices,  and  more
peciﬁcally  to  pacing  and  deﬁbrillation  leads,  have  been
bserved.  Failure  rates  of  15%  at  5  years  and  40%  at  8  years
ave  been  reported  for  deﬁbrillators  leads  [13].  The  use  of
M  appears  to  be  adequate  for  the  early  detection  of  such
ailures.  A  study  of  54  patients  showed  that  monitoring  by
A
m
TM  decreases  the  number  of  inappropriate  shocks  (19.2%)
nd  allows  earlier  detection  of  failure  (54  days)  compared
ith  traditional  follow-up  [14]. A  prospective  single-centre
tudy  (n  =  69)  demonstrated  the  feasibility  and  efﬁcacy  of  RM
or  the  detection  of  deﬁbrillator  failure  [15].  A  gain  of  1.9
onths  in  the  detection  of  adverse  events  compared  with
raditional  follow-up  during  the  ﬁrst  year  and  of  5  months
n  the  following  years  was  observed  [15]. At  the  same  time
s  these  studies,  clinical  cases  demonstrated  the  value  of
M  in  the  early  detection  of  deﬁbrillator  defects  [16,17],
llowing  rapid  patient  management.  A  retrospective  study
n  = 169)  concluded  that  RM  identiﬁed  >  99.5%  of  arrhyth-
ias  and/or  changes  related  to  medical  devices  [5].  Taken
ogether,  these  studies  show  that  RM  allows  the  early  detec-
ion  of  abnormalities  related  to  the  device,  thus  improving
uality  and  patient  security.  Identiﬁcation  of  defects  allows
irect  intervention  to  pre-empt  shock  delivery  and  to  reduce
atient  morbidity  and  premature  battery  depletion  [18].
linical efﬁciency
rrhythmiastrial  arrhythmias,  particularly  atrial  ﬁbrillation  (AF),  are
ajor  risk  factors  for  ischemia,  which  may  induce  stroke.
he  detection  of  these  rhythm  abnormalities  determines
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therapeutic  strategy,  in  terms  of  anticoagulation  and  adjust-
ment  of  the  implanted  device.  RM  of  166  patients  over
a  period  of  16  months  showed  that  26%  had  an  alert  for
AF  [19].  For  78%,  an  unscheduled  consultation  was  carried
out,  followed  by  the  introduction/modiﬁcation  of  medical
treatment  or  of  the  medical  device  [19].  Compared  with  con-
ventional  monitoring,  the  duration  of  the  ﬁrst  intervention
was  50  days,  which  was  a  gain  of  148  days  [19].  The  ﬁrst  pub-
lication  of  The  Lumos-T  Safely  Reduces  Routine  Ofﬁce  Device
Follow-Up  (TRUST)  study  (n  =  1339)  showed  that  arrhythmias
were  the  leading  cause  of  notiﬁcation  and  that  RM  led  to  a
mean  time  of  a  day  for  evaluation  by  the  clinician  compared
with  35.5  days  for  traditional  monitoring  [20].  Furthermore,
the  detection  time  for  AF  was  reduced  from  40  days  to  6
days  [20].
Heart failure progression
New  implantable  devices  have  been  developed  by  manufac-
turers  to  address  the  difﬁculties  in  managing  heart  failure.
As  a  dynamic  pathology,  the  process  of  heart  failure  decom-
pensation  is  complex  but  behaves  as  a  ﬂuid  congestion  [10].
Currently,  data  are  available  to  conﬁrm  that  this  patho-
physiological  process  progresses  over  days  to  weeks  before
clinical  presentation.  With  the  development  of  CRT  devices,
the  initial  events  of  heart  failure  can  be  tracked.  Spe-
ciﬁc  variables,  considered  as  essential,  can  be  followed  up:
hemodynamic,  pulmonary  (pulmonary  artery  pressure),  and
thoracic  (intrathoracic  impedance).  Thanks  to  the  RM  of
heart  failure,  patients  in  decompensation  can  be  rapidly
detected  and  their  therapy  can  be  managed  earlier.  Results
relating  to  this  heart  failure  monitoring  revolution  are
limited  and  controversial  [21—23],  but  many  studies  are  in
progress  to  conﬁrm  the  beneﬁt  of  this  new  approach.
Occurrence of severe adverse events and
reduction in the number of hospital stays,
morbidity and mortality
The  second  publication  from  the  TRUST  study  showed  a  45%
decrease  in  the  number  of  consultations,  without  any  impact
on  morbidity  [24].  The  COMPArative  follow-up  Schedule  with
home  monitoring  (COMPAS)  study  (n  =  538)  demonstrated
non-inferiority  of  RM  in  terms  of  occurrence  of  serious
adverse  events  [25].  The  management  of  notiﬁed  events
was  117  days  earlier  and  a  66%  decrease  in  hospital  stays
for  AF  was  observed.  The  ECOST  (n  =  433)  and  EVAluation
of  TELe  follow-up  (EVATEL)  (n  =  1501)  studies  also  showed
non-inferiority  compared  with  conventional  follow-up  in
terms  of  risk  of  all-cause  mortality  [26,27].  A  highly  sig-
niﬁcant  reduction  in  the  number  of  inappropriate  shocks
was  observed  in  the  RM  group  in  these  two  studies,  with
a  72%  decrease  in  hospital  stays  related  to  these  shocks  in
the  ECOST  study.  Another  study  (n  =  379)  showed,  after  pace-
maker  implantation,  a  reduction  in  adverse  events  (absolute
risk  reduction  of  4.1%)  and  mean  hospitalization  duration
(34%)  [28].  Finally,  a  multicentre  study  (n  >  2000)  showed
that  RM  is  associated  with  a  lower  mortality  rate  among
patients  with  heart  disease  as  well  as  a  signiﬁcant  decrease
in  mean  length  of  stay  (4  days  for  in-ofﬁce  visit  versus  3  days
t
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or  RM  follow-up)  [29].  The  authors  concluded  that  RM  has
 protective  clinical  effect  in  these  patients.
atient quality of life
ew  studies  have  investigated  patient  quality  of  life  and
hey  have  shown  divergent  results.  Compared  with  a  conven-
ional  follow-up  strategy,  no  differences  in  quality  of  life  and
atient  satisfaction  were  reported  in  some  studies  [30].  By
omparison,  other  studies  have  demonstrated  better  quality
f  life  and  patient  satisfaction  with  RM,  although  a  minority
f  patients  found  RM  unacceptable  [31,32]. Several  reasons
an  explain  this  refusal:  fear  of  technology,  loss  of  privacy,
nd  loss  of  human  contact  with  practitioners.  Currently,  edu-
ation  regarding  RM  is  crucial  to  facilitate  acceptance.
rganizational aspects
fﬁcient  organization  of  RM  is  a  prerequisite  to  allow  its
mplementation  in  standard  clinical  practice.  Currently,  dif-
erences  exist  between  countries.  Organization,  frequency
f  monitoring  consultations  and  monitoring  liability  have  to
e  deﬁned  if  RM  is  to  become  the  standard  of  care.
onitoring consultations
n  addition  to  early  detection  of  adverse  events,  better
onitoring  of  patients  is  possible  with  RM,  while  reducing
he  number  of  monitoring  consultations  with  the  cardiol-
gist  and  making  them  more  efﬁcient.  This  reduction  in
he  number  of  consultations  has  been  demonstrated  repeat-
dly  in  different  studies,  with  a  decrease  in  consultations
f  45%  and  56%  in  the  TRUST  [20]  and  COMPAS  [25]  studies,
espectively;  these  decreases  did  not  affect  the  rates  of  hos-
italization  or  mortality.  In  another  study  the  time  required
or  a  traditional  monitoring  visit  compared  with  RM  has  been
etermined  and  showed  substantial  time  saving  (going  from
5.8  minutes  to  4.5  minutes  in  favor  of  RM)  [6].
requency of monitoring
 consensus  on  the  practice  of  RM  and  the  competency  of  the
erson  who  carries  it  out  has  been  proposed  by  European  and
merican  cardiology  societies  [33]. Face-to-face  follow-up
ust  be  carried  out  within  the  72  hours  following  implanta-
ion  and  2—12  weeks  after  device  implantation.  Monitoring
very  3—12  months  for  pacemakers  and  every  3—6  months
or  deﬁbrillators  can  be  carried  out  by  RM.  Whatever  the
ype  of  implant,  an  annual  face-to-face  consultation  with  a
ardiologist  in  an  implant  centre  is  recommended.  Consul-
ations  for  when  the  prosthesis  reaches  the  end  of  its  life
nd  therefore  needs  to  be  replaced  are  planned,  following
he  recordings  obtained  by  RM.
onitoring liability and regulatory aspects
hile  it  seems  clear  from  several  studies  that  RM  reduces
he  number  of  consultations  and  provides  quicker  analysis
f  cardiac  events  and  implant  defects,  health  professional
iability  is  not  yet  well  deﬁned.  RM  is  a medical  procedure
arried  out  by  a  trained  cardiologist.  However,  part  of  the
2 N.  Maillard  et  al.
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Table  3  Indications  for  cardiac  remote  monitoring
systems.
Cardiac  arrest  by  VF  or  VT,  without  acute  or  reversible
cause
Coronary  patients  with  or  without  symptoms  of
mild-to-moderate  heart  failure
Spontaneous  sustained  symptomatic  VT  on  heart  disease
Spontaneous  sustained  VT,  poorly  tolerated,  in  the
absence  of  cardiac  abnormalities,  for  which  medical
treatment  or  ablation  cannot  be  carried  out  or  failed
Syncope  of  unknown  cause  with  sustained  VT  or
inducible  VF,  in  the  presence  of  an  underlying  cardiac
abnormality
Coronary  patients  with  left  ventricular  dysfunction
Patient  with  dilated  cardiomyopathy,  primitive  in
appearance,  with  LVEF  ≤  30%  and  NYHA  class  II  or  III
Genetic  disease  at  high  risk  of  sudden  death  by  VF,  with
no  other  known  effective  treatment
Sustained  VT,  poorly  tolerated,  in  a  patient  waiting  for  a
heart  transplant
LVEF: left ventricular ejection fraction; NYHA: New York Heart
Association; VF: ventricular ﬁbrillation; VT: ventricular
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oncept  of  RM  is  carried  out  by  allied  professionals  delegated
y  the  cardiologist.  Currently,  important  organizational  dif-
erences  exist  between  countries.  The  USA  and  Switzerland
ake  use  of  RM-trained  technicians.  In  the  United  Kingdom,
onitoring  is  carried  out  by  biomedical  engineers,  whereas
urses  carry  out  monitoring  in  Italy.  In  France,  the  situa-
ion  is  heterogeneous,  with  variation  according  to  centre;
urses  or  clinical  research  associates  may  be  involved.  In
he  French  Telecardiology  White  Paper,  the  status  of  the
echnician  specialized  in  rhythmology  was  discussed,  but  no
ecision  was  made  for  the  moment  [34].  Currently,  some  for-
ign  teams  have  delegated  the  monitoring  of  uploaded  data
o  independent  telemedicine  centers  [35].  From  a  medical
iability  perspective,  the  practitioner  has  to  organize  the
echnical  and  human  resources  to  carry  out  RM.  Analysis  of
he  uploaded  data  is  a  requirement  in  the  days  and  hours  of
ork  (obligation  of  means)  [36].  Interestingly,  a  multicentre
talian  registry  has  been  designed  to  analyze  the  manpower
eed  for  RM.  Results  reported  in  the  HomeGuide  Registry
howed  low  manpower  consumption,  with  55.5  minutes  per
ealth-personnel  unit  per  month  per  every  100  patients  [37].
The  information  and  patient  consent  sheet  states  that  the
hysician  is  not  required  to  keep  a  permanent  record.  The
iabilities  of  patients  and  manufacturers  have  to  be  deﬁned.
he  use  of  RM  requires  a  contract  to  be  drafted  between  the
hysician,  the  establishment  concerned  and  the  supplier,  so
hat  the  role  of  each  is  perfectly  deﬁned.  The  supplier  must
rovide  permanent  and  secure  access,  allowing  conﬁdential-
ty  and  protection  of  patient  data.  The  supplier  must  have
 license  for  data  storage,  provide  leadership  in  the  event
f  failure  and  replace  non-functional  RM  material.  RM  also
hows  its  value  in  the  management  of  medical  device  safety
lerts,  such  that  the  offending  device  can  be  tracked  early
nd  material  removed  more  quickly  if  the  patient’s  condition
equires  it.  This  new  technology  requires  the  cardiologist
o  provide  a  ‘‘clear,  fair  and  appropriate’’  explanation  to
he  patient  in  terms  of  the  operating  conditions  of  tele-
onitoring  (Article  35,  Code  of  Ethics).  Written  consent
s  recommended.  It  should  be  emphasized  that  RM  is  not
n  alarm  or  emergency  system  and  should  not  in  any  way
eplace  conventional  cardiac  monitoring  [38].
edico-economic criteria and reﬂection
 number  of  studies  have  highlighted  the  economical  advan-
age  of  RM.  A  theoretical  evaluation  of  cost  reduction
onducted  in  a  French  study  [39]  showed  a  reduction  of
2200  (United  States  dollars  [USD])  per  year  and  per  patient
f  the  number  of  visits  is  reduced  from  4  to  2  and  of  $3300
USD)  for  one  visit  per  year.  The  important  decrease  in
he  overall  cost  is  depicted  by  transportation  cost.  In  the
ranco-Belgian  study  ŒDIPE,  reducing  the  length  of  stay  also
rought  about  a  medico-economic  advantage  for  RM  [28].
nother  study  estimated  a  cost  reduction  over  5  years  of
etween  $2100  and  $3300  (USD)  [6].  The  prevention  of  acute
vents  and  the  limitation  of  hospitalizations  also  decrease
esource  consumption  with  RM,  as  shown  in  the  COMPAS
rial,  with  fewer  hospitalizations  for  atrial  arrhythmias  and
trokes  [25].  Other  studies  (ECOST,  EVATEL,  EUROECO,  etc.)
ith  cost  analysis  as  primary  or  secondary  endpoints  should
oon  give  consistent  results.  Interestingly,  a  recent  statisti-
al  analysis  using  the  Markov  model  showed  that  RM  is  cost
m
b
dtachycardia.
eutral  over  10  years  compared  with  conventional  follow-
p  [40]. In  Italy,  the  TARIFF  study  is  in  progress  and  should
rovide  some  answers;  the  results  of  this  study  should  be
dapted  to  the  speciﬁcities  of  each  country  [41].
These  medico-economic  data  are  important  in  show-
ng  the  value  of  cardiac  RM  and  in  France  they  are  also
sed  by  manufacturers  to  support  their  inclusion  on  the
ist  of  Reimbursable  Products  and  Services  (Liste  des  Pro-
uits  et  Prestations  Remboursables  [LPPR].  The  difﬁculty  in
ransposing  these  studies  between  countries  must,  never-
heless,  be  highlighted.  Indeed,  differences  in  health  care
ystems  are  particularly  important  and  reimbursement  poli-
ies  for  RM  vary  extensively  among  different  countries.
nlike  many  countries  in  Europe  (Germany,  Portugal,  the
nited  Kingdom,  Netherlands,  Sweden,  Denmark  and  Fin-
and),  the  complexity  of  the  French  hospital  care  system
as  resulted  in  important  delays  and  aberrations.
In  France,  the  economic  and  organizational  environment
f  the  hospital  health  system  is  based  on  activity-based
ariffs.  The  ﬁrst  RM  devices  were  registered  on  the  list
f  invoiced  products  and  included  in  homogeneous  hospi-
al  stay  groups  (groups  homogènes  de  séjours  [GHS])  in
eptember  2011.  Ironically,  a  few  months  before,  the  man-
gement  of  deﬁbrillators  (not  pacemakers  !)  was  removed
rom  inclusion  in  GHS.  At  present,  the  Home  Monitoring®,
areLink® et  Latitude® systems  receive  an  additional  refund
f  D  864  when  they  are  associated  with  single-  and  double-
hamber  deﬁbrillators  and  D  972  for  triple-chamber  devices
42]. Today,  only  the  Biotronik  system  has  a speciﬁc  regis-
ration  for  pacemakers;  they  are  only  paid  when  they  are
ssociated  with  implanted  cardiac  deﬁbrillators  (or  a  pace-
aker  for  Biotronik),  according  to  the  directions  speciﬁed
y  the  LPPR  (Table  3).
In  France,  a  lack  of  ﬁnancial  compensation  prevents  car-
iologists  from  wider  deployment  of  RM.  In  addition  to
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the  act  of  RM,  reimbursement  must  take  into  account  the
structural  costs  incurred  to  ensure  this  activity:  technical
(hardware  maintenance  and  security,  high  speed  internet
connection,  etc.)  and  human  resources  (doctors  and  other
health  professionals  trained  in  the  practice  of  RM).  An  anal-
ysis  of  health  services  in  Ontario  (Canada)  estimated  the
consultation  fee  as  part  of  conventional  (face-to-face)  mon-
itoring  at  approximately  $140  (Canadian  dollars  [CAD])  and
approximately  $105  (CAD)  for  RM  due  to  reduced  consulta-
tion  time  and  less  use  of  transport  by  patients;  this  results
in  a  health  insurance  gain  of  approximately  $100  (CAD)  per
patient  and  per  year  [43].  The  situation  in  Europe  varies
extensively.  RM  is  paid  for  in  Finland,  Germany,  Portugal
and  the  Netherlands,  but  not  in  Italy,  Belgium  and  Den-
mark.  In  France,  discussions  are  ongoing  and  reﬂection  is
led  jointly  by  the  National  Council  of  the  College  of  Physi-
cians,  the  National  Professional  Council  of  Cardiology  and
the  French  Society  of  Cardiology.  The  main  areas  are  out-
lined  in  the  report  entitled  ‘‘Economic  thinking  for  payment
of  ambulatory  RM  of  patients  with  pacemakers  and  cardiac
deﬁbrillators’’.  One  proposal  is  for  an  annual  fee  to  cover
RM;  this  fee  would  include  payment  of  the  health  profes-
sional,  the  cost  of  RM  installation  in  the  patient’s  home
(technical  and  medical  time)  and  costs  relating  to  the  struc-
ture  housing  the  RM  system  and  the  premises  necessary  to
carry  out  RM  of  patients.  An  annual  fee  for  RM,  paid  by  health
insurance,  of  approximately  D  230  and  D  250  per  year  has
been  proposed  for  patients  with  a  pacemaker  or  deﬁbrilla-
tor,  respectively.  An  additional  reimbursement  could  be  also
proposed  for  the  ﬁrst  year  regarding  RM  installation  and  edu-
cation  of  patient.  Currently,  the  delivery  of  RM  devices  at
the  ﬁrst  consultation  is  subject  to  a  fee  of  D  12.60  for  the
administration  of  products  and  services  in  a  hospital  envi-
ronment.  In  order  to  have  a  balanced  model,  it  is  necessary
that  the  activity  of  RM  is  valued  at  a  fair  cost,  without  for-
getting  the  manufacturer  whose  role  in  the  implementation
of  the  service  is  pivotal.
Conclusion
RM  is  an  innovative  paradigm  that  could  supplant  conven-
tional  episodic  in-ofﬁce  device  interrogation.  Advantages
include  earlier  detection  of  patient  events  (arrhythmia
onset  and  device  therapy),  programming  issues  (therapies
programmed  off)  and  device  integrity  problems  (notably
lead  fracture).  Moreover,  patient  and  physician  satisfaction
have  been  largely  demonstrated.  In  this  context,  it  would  be
too  simplistic  to  think  that  RM  has  become  a  gold  standard  in
the  management  of  patients  and  in  the  daily  activity  of  car-
diologists.  The  reality  is  much  less  attractive  and  shows  large
disparities  between  countries.  Countries  where  RM  can  be
considered  as  a  gold  standard  have  quickly  deﬁned  modal-
ities  of  reimbursement  as  well  as  the  liabilities  of  those
involved  (patients,  health  professionals,  manufacturers,  the
health  establishment).  In  France,  there  has  been  an  impor-
tant  delay  regarding  these  items,  which  has  led  to  limited
implementation  of  RM.  Further  discussions  should  be  initi-
ated  promptly  to  catch  up,  especially  in  view  of  the  ageing
population,  the  announced  reduction  in  the  number  of  car-
diologists  and  the  emergence  of  indications,  such  as  heart
failure.
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